JP Morgan Chase
ZVRA icon

JP Morgan Chase’s Zevra Therapeutics ZVRA Stock Holding History

JP Morgan Chase’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-75,000
Closed -$962K – 6865
2021
Q2 		$962K Hold
75,000
– – ﹤0.01% 4320
2021
Q1 		$690K Buy
+75,000
New +$655K ﹤0.01% 4475

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

JP Morgan Chase's ZVRA Position: Q1 2026 in Review

JP Morgan Chase reduced its Zevra Therapeutics (ZVRA) stake by 8.1% in Q1 2026, selling an estimated $300K and leaving 378,932 shares worth $3.33M. The position accounts for ﹤0.01% of the portfolio, ranked #3690.

JP Morgan Chase first reported a position in ZVRA in Q2 2015 and has held it in 30 quarters since. The position peaked at $4.17M in Q3 2025. 148 funds tracked by Wall St. Rank hold ZVRA as of Q1 2026.

  • JP Morgan Chase held 378,932 shares of Zevra Therapeutics worth $3.33M as of Q1 2026.
  • JP Morgan Chase sold 33,329 Zevra Therapeutics shares in Q1 2026, an estimated $300K.
  • Zevra Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #3690 holding.
  • JP Morgan Chase first reported a position in Zevra Therapeutics in Q2 2015 and has held it in 30 quarters since.
  • JP Morgan Chase's Zevra Therapeutics position peaked at $4.17M in Q3 2025.
  • 148 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.